Biofront Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 3

Biofront Therapeutics General Information

Description

Developer of drug discovery platforms intended for multinational pharmaceutical companies, biotech investors, and clinical research institutions. The company's drug discovery platform integrates early de-risking capabilities, proprietary wet-lab technologies, and a multidisciplinary team experienced, thereby enabling partners to gain access to high-quality preclinical candidates and scalable innovation pipelines.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 101, 1st to 4th Floor, Building 16
  • Number 9 Yongteng North Road, Haidian District
  • Beijing, 100094
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Room 101, 1st to 4th Floor, Building 16
  • Number 9 Yongteng North Road, Haidian District
  • Beijing, 100094
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biofront Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 01-Jun-2025 Completed Generating Revenue
1. Early Stage VC 29-Dec-2020 Completed Generating Revenue
To view Biofront Therapeutics’s complete valuation and funding history, request access »

Biofront Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biofront Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Panacea Capital (California) Venture Capital Minority
Capital Science and Technology Development Group Venture Capital Minority
ZGC Science City Growth/Expansion Minority
To view Biofront Therapeutics’s complete investors history, request access »

Biofront Therapeutics Investments (1)

Biofront Therapeutics’s most recent deal was a Seed Round with ComMedX. The deal was made on 01-Dec-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ComMedX 01-Dec-2020 Seed Round Discovery Tools (Healthcare)
To view Biofront Therapeutics’s complete investments history, request access »

Biofront Therapeutics FAQs

  • When was Biofront Therapeutics founded?

    Biofront Therapeutics was founded in 2018.

  • Where is Biofront Therapeutics headquartered?

    Biofront Therapeutics is headquartered in Beijing, China.

  • What is the size of Biofront Therapeutics?

    Biofront Therapeutics has 6 total employees.

  • What industry is Biofront Therapeutics in?

    Biofront Therapeutics’s primary industry is Drug Discovery.

  • Is Biofront Therapeutics a private or public company?

    Biofront Therapeutics is a Private company.

  • What is Biofront Therapeutics’s current revenue?

    The current revenue for Biofront Therapeutics is .

  • Who are Biofront Therapeutics’s investors?

    Panacea Capital (California), Capital Science and Technology Development Group, and ZGC Science City have invested in Biofront Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process